参考文献/References:
[1] Kong P,Cui ZY,Huang XF,et al. Inflammation and atherosclerosis:signaling pathways and therapeutic intervention[J]. Signal Transduct Target Ther,2022,7(1):131.
[2] Libby P. Inflammation during the life cycle of the atherosclerotic plaque[J]. Cardiovasc Res,2021,117(13):2525-2536.
[3] Ridker PM,Everett BM,Thuren T,et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med,2017,377(12):1119-1131.
[4] Tardif JC,Kouz S,Waters DD,et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med. 2019,381(26):2497-2505.
[5] Nidorf SM,Fiolet ATL,Mosterd A,et al. Colchicine in patients with chronic coronary disease[J]. N Engl J Med,2020,383(19):1838-1847.
[6] Ridker PM,Bhatt DL,Pradhan AD,et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy:a collaborative analysis of three randomised trials[J]. Lancet,2023,401(10384):1293-1301.
[7] Ross R. Atherosclerosis--an inflammatory disease[J]. N Engl J Med,1999,340(2):115-126.
[8] Gora IM,Ciechanowska A,Ladyzynski P. NLRP3 inflammasome at the interface of inflammation,endothelial dysfunction,and type 2 diabetes[J]. Cells,2021,10(2):314.
[9] Tanase DM,Valasciuc E,Gosav EM,et al. Portrayal of NLRP3 inflammasome in atherosclerosis:current knowledge and therapeutic targets[J]. Int J Mol Sci,2023,24(9):8162.
[10] Poznyak AV,Melnichenko AA,Wetzker R,et al. NLPR3 inflammasomes and their significance for atherosclerosis[J]. Biomedicines,2020,8(7):205.
[11] Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1:moving upstream to identify novel targets for atheroprotection[J]. Circ Res,2016,118(1):145-156.
[12] Attiq A,Afzal S,Ahmad W,et al. Hegemony of inflammation in atherosclerosis and coronary artery disease[J]. Eur J Pharmacol,2024,966:176338.
[13] Libby P,Tabas I,Fredman G,et al. Inflammation and its resolution as determinants of acute coronary syndromes[J]. Circ Res,2014,114(12):1867-1879.
[14] Oikonomou EK,Antonopoulos AS,Schottlander D,et al. Standardized measurement of coronary inflammation using cardiovascular computed tomography:integration in clinical care as a prognostic medical device[J]. Circ Res,2021,117(13):2677-2690.
[15] Suzuki K,Kinoshita D,Yuki H,et al. Higher noncalcified plaque volume is associated with increased plaque vulnerability and vascular inflammation[J]. Circ Cardiovasc Imaging,2024,17(1):e015769.
[16] Antonopoulos AS,Angelopoulos A,Tsioufis K,et al. Cardiovascular risk stratification by coronary computed tomography angiography imaging:current state-of-the-art[J]. Eur J Prev Cardiol,2022,29(4):608-624.
[17] Oikonomou EK,Marwan M,Desai MY,et al. Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study):a post-hoc analysis of prospective outcome data[J]. Lancet,2018,392(10151):929-939.
[18] Coerkamp CF,Verpalen VA,Kuipers RS,et al. Perivascular fat attenuation index (FAI) on computed tomography coronary angiography reclassifies individual cardiovascular risk estimation[J]. Int J Cardiol Cardiovasc Risk Prev,2025,24:200360.
[19] Lu Z-F,Yin W-H,Schoepf UJ,et al. Prediction value of pericoronary fat attenuation index for coronary in-stent restenosis[J]. Eur Radiol,2024,34(8):4950-4959.
[20] Cheng K,Hii R,Lim E,et al. Effect of statin therapy on coronary inflammation assessed by pericoronary adipose tissue computed tomography attenuation[J]. Eur Heart J Cardiovasc Imaging,2025,26(5):784-793.
[21] Christen T,Sheikine Y,Rocha VZ,et al. Increased glucose uptake in visceral versus subcutaneous adipose tissue revealed by PET imaging[J]. JACC Cardiovasc Imaging,2010,3(8):843-851.
[22] Jamialahmadi T,Reiner ?,Simental-Mendia LE,et al. Effect of statins on arterial wall inflammation as assessed by 18F-FDG PET CT:an updated systematic review and meta-analysis[J]. J Inflamm (Lond),2024,21(1):52.
[23] Pelletier-Galarneau M,Ruddy TD. Molecular imaging of coronary inflammation[J]. Trends Cardiovasc Med,2019,29(4):191-197.
[24] Mehta NN,Torigian DA,Gelfand JM,et al. Quantification of atherosclerotic plaque activity and vascular inflammation using[18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT)[J]. J Vis Exp,2012,(63):e3777.
[25] Joshi NV,Vesey AT,Williams MC,et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques:a prospective clinical trial[J]. Lancet,2014,383(9918):705-713.
[26] Naik HB,Natarajan B,Stansky E,et al. Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET/CT and neutrophil activation in a prospective observational study[J]. Arterioscler Thromb Vasc Biol,2015,35(12):2667-2676.
[27] Kwiecinski J,Dey D,Cadet S,et al. Peri-coronary adipose tissue density is?associated with 18F-sodium fluoride coronary uptake in stable patients with?high-risk plaques[J]. JACC Cardiovasc Imaging,2019,12(10):2000-2010.
[28] Lieverse TGF,van Praagh GD,Mulder DJ,et al. Quantitative aortic Na[18F]F positron emission tomography computed tomography as a tool to associate vascular calcification with major adverse cardiovascular events[J]. Eur J Nucl Med Mol Imaging,2024,52(2):501-509.
[29] Choi Y-J,Yang S,West H,et al. Association of coronary inflammation with plaque vulnerability and fractional flow reserve in coronary artery disease[J]. J Cardiovasc Comput Tomogr,2025,19(1):32-39.
[30] Alam SR,Stirrat C,Richards J,et al. Vascular and plaque imaging with ultrasmall superparamagnetic particles of iron oxide[J]. J Cardiovasc Magn Reson ,2015,17(1):83.
[31] Smits LP,Tiessens F,Zheng KH,et al. Evaluation of ultrasmall superparamagnetic iron-oxide (USPIO) enhanced MRI with ferumoxytol to quantify arterial wall inflammation[J]. Atherosclerosis,2017,263:211-218.
[32] 冷玉杰,于雪. 冠状动脉磁共振成像的临床应用及研究进展[J]. 中国心血管杂志,2025,30(2):143-147.
[33] Liu W,Wu S,Wang Z,et al. Relationship between coronary hyper-intensive plaques identified by cardiovascular magnetic resonance and clinical severity of acute coronary syndrome[J]. J Cardiovasc Magn Reson,2021,23(1):12.
[34] Hosoda H,Asaumi Y,Noguchi T,et al. Three-dimensional assessment of coronary high-intensity plaques with T1-weighted cardiovascular magnetic resonance imaging to predict periprocedural myocardial injury after elective percutaneous coronary intervention[J]. J Cardiovasc Magn Reson,2020,22(1):5.
[35] Carpenter HJ,Ghayesh MH,Zander AC,et al. Automated coronary optical coherence tomography feature extraction with application to three-dimensional reconstruction[J]. Tomography,2022,8(3):1307-1349.
[36] Gutierrez-Chico JL,Alegria-Barrero E,Teijeiro-Mestre R,et al. Optical coherence tomography:from research to practice[J]. Eur Heart J Cardiovasc Imaging,2012,13(5):370-384.
[37] Koiwaya H,Tahara N,Tahara A,et al. In?vivo molecular imaging of ruptured coronary atherosclerotic plaque using IVUS,OCT,and FDG-PET/CT[J]. JACC Cardiovasc Interv,2016,9(12):e113-e115.
[38] Karady J,Ferencik M. Combined assessment of quantitative coronary plaque characteristics and perivascular inflammation for better detection of high risk[J]. Circ Cardiovasc Imaging,2024,17(1):e016364.
[39] Iannaccone M,Quadri G,Taha S,et al. Prevalence and predictors of culprit plaque rupture at OCT in patients with coronary artery disease:a meta-analysis[J]. Eur Heart J Cardiovasc Imaging,2016,17(10):1128-1137.
[40] Sugiyama T,Kanaji Y,Hoshino M,et al. Relationship of OCT-defined plaque characteristics with CCTA-derived coronary inflammation and CMR-derived global coronary flow reserve in patients with acute coronary syndrome[J]. PLoS One,2023,18(5):e0286196.
[41] Gili S,Iannaccone M,Colombo F,et al. Effects of statins on plaque rupture assessed by optical coherence tomography in patients presenting with acute coronary syndromes:insights from the optical coherence tomography (OCT)-FORMIDABLE registry[J]. Eur Heart J Cardiovasc Imaging,2018,19(5):524-531.
[42] Li J,Ma T,Mohar D,et al. Ultrafast optical-ultrasonic system and miniaturized catheter for imaging and characterizing atherosclerotic plaques in vivo[J]. Sci Rep,2015,5:18406.
[43] Giacoppo D,Laudani C,Occhipinti G,et al. Coronary angiography,intravascular ultrasound,and optical coherence tomography for guiding of percutaneous coronary intervention:a systematic review and network meta-analysis[J]. Circulation,2024,149(14):1065-1086.
[44] Nicholls SJ,Puri R,Anderson T,et al. Effect of evolocumab on progression of coronary disease in statin-treated patients:the GLAGOV randomized clinical trial[J]. JAMA,2016,316(22):2373-2384.
相似文献/References:
[1]胥雪莲,何川.炎症与动脉粥样硬化[J].心血管病学进展,2015,(5):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
XU Xuelian,HE Chuan.Inflammation and Atherosclerosis[J].Advances in Cardiovascular Diseases,2015,(11):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
[2]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(11):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[3]赵丹 周鹏.达比加群及其逆转剂在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):801.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.034]
ZHAO DanZHOU Peng.Dabigatran and Reversal in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(11):801.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.034]
[4]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(11):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[5]陈元 楚天舒 武力勇.瘦素抵抗、瘦素受体基因多态性与冠状动脉粥样硬化性心脏病的相关性进展[J].心血管病学进展,2019,(8):1130.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.015]
CHEN Yuan,CHU Tianshu,WU Liyong.Leptin Resistance,Leptin Receptor Gene Polymorphism and Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(11):1130.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.015]
[6]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(11):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[7]宋志平 杨永健.GPR 35在心血管疾病中的研究进展[J].心血管病学进展,2019,(9):1304.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.031]
SONG Zhiping,YANG Yongjian.The Current Progress of GPR 35 in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1304.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.031]
[8]顾佳仪 刘正霞 鲁翔.白介素-1β在冠心病中的研究进展[J].心血管病学进展,2020,(2):125.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.006]
Gu Jiayi,Liu Zhengxia,Lu Xiang.Interleukin-1 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(11):125.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.006]
[9]王辉 蒋永兴 田野.下肢动脉硬化闭塞症：炎症机制与抗炎治疗的研究进展[J].心血管病学进展,2020,(2):179.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.020]
WANG HuiJIANG YongxingTIAN Ye.Peripheral Arterial DiseaseA Research Progress Review of Inflammatory Mechanism and Anti-inflammatory Therapy[J].Advances in Cardiovascular Diseases,2020,(11):179.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.020]
[10]严宁,杨春霞,马娟,等.β-谷甾醇对大鼠心肌缺血再灌注损伤和ERK1/2信号通路的影响[J].心血管病学进展,2020,(3):321.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.026]
YAN Ning,YANG Chunxia,MA Juan,et al.Effects of -sitosterolon Myocardial Ischemia-reperfusion Injury and ERK1/2 Signaling Pathway in Rats[J].Advances in Cardiovascular Diseases,2020,(11):321.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.026]
[11]吉蓉 寿锡凌.秋水仙碱在冠状动脉粥样硬化性心脏病防治中的研究进展与争议[J].心血管病学进展,2022,(1):60.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.016]
JI Rong,SHOU Xiling.Research Progress and Controversy of Colchicine in Prevention and Treatment of Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2022,(11):60.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.016]
[12]曾祥烨 王蔚宗 周桐羽 杜晓诗 孟庆欣 李丙松 高梅.冠状动脉扩张症：非冠状动脉粥样硬化性心脏病的特殊类型[J].心血管病学进展,2024,(10):902.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.008]
ZENG Xiangye,WANG Weizong,ZHOU Tongyu,et al.Coronary Artery Ectasia:A Specialized Type of Non-Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2024,(11):902.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.008]